Cardiac Allograft Vasculopathy
Conditions
Keywords
Donor-derived Cell Free DNA, Heart Transplant
Brief summary
Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.
Interventions
DIAGNOSTIC_TESTDonor-derived Cell Free DNA
We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification
Sponsors
Puerta de Hierro University Hospital
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients over 18 and under 80 years old, HT \> 1 year ago
Exclusion criteria
* Patients under 18 or over 80 years old * Multiorgan transplant * History of acute cellular rejection ≥ 1R or antibody mediated rejection in the previous 6 months * Concomitant infection by CMV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between ddcf-DNA and CAV | 2 years | Correlation between ddcf-DNA levels and the presence of any degree of CAV (CAV0 vs CAV1, 2, or 3) |
| Performance of the biomarker for the diagnosis of CAV | 2 years | Determine the performance of this biomarker in this situation using receiver-operator characteristics analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of ddcf-DNA with the different degrees of CAV (0, 1, 2 and 3) | 2 years | Correlation of ddcf-DNA with the different degrees of CAV (0, 1, 2 and 3) |
| Correlation of ddcf-DNA with other biomarkers (NTproBNP and troponin I) | 2 years | Correlation of ddcf-DNA with other biomarkers (NTproBNP and troponin I) |
Countries
Spain
Outcome results
None listed